X4 Pharmaceuticals, Inc.
XFORAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jul 10, 2026 | Wells Fargo | $11.00(+178%) | $3.96 | TheFly | |
| Jun 2, 2026 | Leerink Partners | Thomas Smith | $12.00(+192%) | $4.11 | TheFly |
| Mar 9, 2026 | Guggenheim | $12.00(+189%) | $4.15 | TheFly | |
| Dec 5, 2025 | Stifel Nicolaus | James Condulis | $10.00(+163%) | $3.80 | TheFly |
| Nov 5, 2025 | Stifel Nicolaus | Stephen Willey | $7.50(+109%) | $3.60 | StreetInsider |
| Aug 29, 2025 | Stifel Nicolaus | Stephen Willey | $9.00(+133%) | $3.87 | TheFly |
| Aug 13, 2025 | H.C. Wainwright | Swayampakula Ramakanth | $3.50(+36%) | $2.58 | TheFly |
| Dec 22, 2022 | Cantor Fitzgerald | $3.00(+253%) | $0.85 | Benzinga | |
| Dec 11, 2022 | Piper Sandler | Edward Tenthoff | $3.00(+223%) | $0.93 | TheFly |
| Nov 30, 2022 | H.C. Wainwright | $5.00(+170%) | $1.85 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Stifel | maintain | Buy | Dec 5, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 10, 2025 |
| Stifel | maintain | Buy | Aug 29, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 27, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Mar 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 14, 2025 |
| Stifel | maintain | Buy | Nov 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 28, 2024 |
| Cantor Fitzgerald | maintain | Overweight | May 31, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 30, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2024 |
| B. Riley Securities | downgrade | Buy →Neutral | Dec 12, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2023 |
| Stifel | maintain | Buy | May 17, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 5, 2023 |
| B. Riley Securities | maintain | Buy | Apr 10, 2023 |
| Oppenheimer | maintain | Outperform | Mar 24, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Mar 22, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Dec 22, 2022 |
| Piper Sandler | maintain | Overweight | Dec 12, 2022 |
Earnings History
Next report: Mar 16, 2027 · EPS est. $-0.22| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.16 | $-0.17 | $2.9M | $2.8M |
| Aug 7, 2026 | $-0.13 | $-0.18 | $8.8M | $2.4M |
| May 6, 2026 | $-0.16 | $-0.20 | $2.7M | $3.2M |
| Mar 17, 2026 | $-0.22 | $-0.36 | $2.6M | $1.7M |
| Nov 5, 2025 | $-0.69 | $-0.79 | $1.8M | $1.9M |
| Aug 8, 2025 | $-3.47 | $-4.53 | $2.0M | $1.6M |
| May 1, 2025 | $0.04 | $-4.13 | $28.8M | $11.6M |
| Mar 25, 2025 | $-6.01 | $-5.11 | $1.4M | $1.1M |
News
X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.69 per share a year ago.
- 4WARD Phase 3 Chronic Neutropenia Trial Expected to Achieve Target Enrollment in Q4 2026 -
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in several upcoming investment conferences in November 2026:
Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) all drawing elevated volume.
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript
- Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients -
X4 Pharmaceuticals NASDAQ: XFOR said it expects to complete enrollment in its pivotal Phase III 4WARD trial of mavorixafor for primary chronic neutropenia, or PCN, by the end of the fourth quarter of 2026, with top-line data anticipated in the first quarter of 2028.
Entrada Therapeutics (NASDAQ: TRDA - Get Free Report) and X4 Pharmaceuticals (NASDAQ: XFOR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability. Insider and Institutional Ownership 86.4% of Entrada
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET.
- Repayment of Existing Loan Facility Completed - - Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities - - Expect Completion of Enrollment in Phase 3 4WARD trial by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that it has entered into a senior secured term loan facility of up to …
Shares of X4 Pharmaceuticals, Inc. (NASDAQ: XFOR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy
BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on September 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of…
X4 Pharmaceuticals (XFOR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Shares of X4 Pharmaceuticals, Inc. (NASDAQ: XFOR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating
X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET.
- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the positive outcome of its Type C Meeting with the U.S. Food and Drug Administration (FDA) related to the global 4WARD Phase 3 clinical trial.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”).
X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).